ESMO Congress 2026

Long-term outcomes along the main treatment axis of prostate cancer form the backdrop for later-line needs. In a multi-institutional cohort of 12,677 radical prostatectomy patients, 15-year prostate cancer-specific mortality (PCSM) was 12%, and among patients stratified by a PSA-recurrence nomogram, the highest quartile reached an estimated PCSM of 38% ^[4]. Across 7,316 patients treated with surgery or radiotherapy at 44 institutions, surgery-managed patients with high- or intermediate-risk disease showed a relative risk of PCSM of 14.2 versus the low-risk group ^[2]. After high-dose IMRT to 86.4 Gy in 1,002 patients, 7-year PCSM in the high-risk group remained 8.1% ^[6]. Meanwhile, ADT, a backbone after progression, carries a competing cardiovascular mortality concern that was the subject of a joint statement by multiple medical societies and an FDA safety warning, and was tested in a meta-analysis of 8 randomized trials enrolling 4,141 patients ^[3]. Together these data show that a definite lethal trajectory persists despite standard local therapy and ADT, making treatment options and safety management in mCRPC a practical question.

At #ESMO26, Johanna S. Enke, MD, of UCLA Health presented interim safety data from a phase 2 study of lutetium Lu 177 vipivotide tetraxetan (Lu 177-labeled) rechallenge in mCRPC. The two OncLive posts point to the same presentation: one is an opening introduction noting that Enke is discussing a trial of the agent in prostate cancer; the other highlights the interim safety findings on “retreatment” with a video link. Notably, the posts themselves disclose no specific figures such as sample size, number of administrations, or adverse event rates; safety details await the full report and meeting materials.

Relative to existing knowledge, the advance here lies in shifting the question to the retreatment setting: the background literature concentrates on long-term PCSM and competing mortality after localized surgery, radiotherapy, and ADT ^[2][3][4][6], and does not address reuse of the same agent after prior exposure. Within a treatment landscape where ADT's cardiovascular competing risk has been repeatedly scrutinized ^[3], the safety of rechallenge directly bears on whether such an agent can re-enter the treatment sequence. Whether the interim data show new safety signals, or whether the rechallenge safety profile matches the initial-treatment phase, cannot be answered, as the posts provide no comparable specifics, and no inference is made here.

The limitations are equally clear: this reading relies solely on the meeting posts and the cited background literature; the former contain no efficacy or safety numbers, and the latter derive from localized-disease populations and cannot be directly extrapolated to the mCRPC rechallenge population. Conclusions should await the full meeting release, and this article does not constitute investment advice.